Clinical Trial Detail

NCT ID NCT02639234
Title Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gradalis, Inc.
Indications

lung non-small cell carcinoma

Therapies

FANG vaccine + Nivolumab

Age Groups: adult

No variant requirements are available.